据港交所8月25日披露，劲方医药科技(上海)股份有限公司(简称：劲方医药)通过港交所上市聆讯，中信 证券为其独家保荐人。 公司共拥有72项已授权专利及117项专利申请(包括8项PCT申请)。在中国、美国、欧盟和其他海外司法 管辖区分别持有2项、1项、1项和8项与GFH925相关的已授权专利；及在中国、美国、欧盟、PCT和其 他海外司法管辖区分别持有5项、4项、3项、1项和21项与GFH925相关的专利申请。 于2023年及2024年以及截至2025年4月30日止四个月，公司的收入主要来自三名与多项履约责任有关的 客户，包括(1)知识产权的授权；(2)研发服务及(3)2024年提供药物。公司一般向客户授予自收到发票后 次月第一日起计为期30天至60天的信贷期。该两名客户均非公司的供应商。 | 量覆]的[編纂]數目 | :[编纂]股H股(視乎[編纂] | | --- | --- | | | 及[編纂]行使與否而定) | | [編纂]數目 | .. [编纂]股H股(可予[編纂]) | | [編纂]數目 | .. [編纂]股H股(可予[編纂]及 | | | 視乎[編纂]及[編纂] | | | 行使與否而定) | | ...

智通财经APP获悉，据港交所8月25日披露，劲方医药科技(上海)股份有限公司(简称：劲方医药)通过港 交所上市聆讯，中信证券为其独家保荐人。 招股书显示，劲方医药是一家生物制药公司，专注于肿瘤(涵盖多种实体瘤的不同治疗线)以及自体免疫 和炎症性疾病领域的开发新治疗方案。截至2025年8月18日，公司已建立起一条产品管线，包括八款候 选药品，其中五款处于临床开发阶段，包括两款核心产品GFH925和GFH375。 GFH925(fulzerasib，商品名达伯特®)是一款公司自主发现的新药物，已在中国获商业化批准，其用于治 疗晚期非小细胞肺癌(NSCLC)，为中国首款以及全球第三款获批的选择性Kirsten大鼠肉瘤(KRAS)G12C 抑制剂。 GFH375是一款KRASG12D的口服生物可利用小分子抑制剂。公司已在中国启动针对携带KRAS G12D突 变的晚期实体瘤患者的I/II期临床试验的II期部分。KRAS G12D是最常见的致癌基因KRAS突变，尚无获 批的治疗方案可用。该突变见于多种癌症类型中，包括约35%的胰腺癌、12%的结直肠癌和4%的非小细 胞肺癌。 公司共拥有72项已授权专利及117项专利申请( ...

Core Viewpoint - Jinfang Pharmaceutical Technology (Shanghai) Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [1] Company Overview - Jinfang Pharmaceutical is a biopharmaceutical company focused on developing new treatment solutions for oncology, autoimmune, and inflammatory diseases [4][6] - The company has established a product pipeline consisting of eight candidate drugs, five of which are in clinical development [4] Key Products - GFH925 (fulzerasib), a selective KRAS G12C inhibitor, has been commercially approved in China for treating advanced non-small cell lung cancer (NSCLC), making it the first of its kind in China and the third globally [4] - GFH375 is an oral small molecule inhibitor targeting KRAS G12D, with ongoing Phase I/II clinical trials in China for patients with advanced solid tumors carrying the KRAS G12D mutation [4][6] Research and Development - The company aims to diversify its product pipeline beyond RAS drug matrices, including GFS202A, a bispecific antibody targeting GDF15 and IL-6, and GFH312, a small molecule drug targeting RIPK1 [4][6] - R&D expenses for 2023 and 2024 are projected to be approximately RMB 313 million and RMB 332 million, accounting for 86.2% and 85.1% of total operating expenses, respectively [6] Financial Performance - Revenue for 2023 and 2024 is estimated at approximately RMB 73.73 million and RMB 105 million, with net losses of approximately RMB 508 million and RMB 678 million for the same periods [6][7] - The fluctuations in net losses are primarily attributed to significant investments in R&D activities and changes in the fair value of equity redemption liabilities due to the company's rising valuation [6]